Prof. Dr. Yuri (Jurijus) Gleba, CEO and majority shareholder of NOMAD Bioscience, has supported Ukrainian Army by donating 100 thousand Euro to reinforce the defense against Russian aggression

Prof. Dr. Yuri (Jurijus) Gleba, CEO and majority shareholder of NOMAD Bioscience, has supported Ukrainian Army by donating 100 thousand Euro to reinforce the defense against Russian aggression

Prof. Dr. Yuri (Jurijus) Gleba, renown scientist and entrepreneur, CEO and major shareholder of Nomad Bioscience GmbH, a German biotechnology company, has donated 100 thousand Euro to the Armed Forces of Ukraine to support the defense against Russian aggression. Prof. Gleba also pledged his future support and expressed his gratitude to all researchers and businessmen worldwide who condemned the war of terrorist Russian state against Ukraine and are supporting Ukrainians in their patriotic fight.

Dr. A. Gyrych, CSO of NOMAD, Prof. Y. Gleba, and other Nomad colleagues are actively supporting Ukraine by donations, helping refugees, and providing help to their colleagues and other people in Ukraine.

About NOMAD

Nomad Bioscience GmbH, headquartered in Munich, Germany, is a private biotechnology company developing plant-made biopharmaceuticals, food additives, biomaterials and agronomic traits that address critical unmet needs. NOMAD’s plant-based transient protein expression technologies are licensed to several companies for a broad range of products. NOMAD’s product pipeline consists of several selected protein candidates for human and animal health, food safety and taste modification including antimicrobial proteins (colicins, lysins and other bacteriocins), antiviral proteins such as griffithsin and other lectins, as well as taste modifying proteins including thaumatins.

Website: www.nomadbioscience.com

Related articles

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend their Research and Development Agreement

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend their Research and Development Agreement Nomad Bioscience GmbH, Munich,…

NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins

NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins Munich, October 2022 – NOMAD Bioscience GmbH has…

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas NOMADS UAB, Lithuania,…

NOMAD Bioscience Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at Industrial Manufacturing of Its Protein Products

NOMAD BIOSCIENCE Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at…
Menü